Explore the groundbreaking advancements in PCSK9 research over the past two decades in this comprehensive 59-minute lecture by Dr. Michael D. Shapiro, a renowned cardiologist from Wake Forest University. Delve into the evolution of PCSK9 inhibitors and their impact on cardiovascular medicine, gaining valuable insights into the latest developments in lipid management and atherosclerosis prevention. Learn about the molecular mechanisms, clinical applications, and future prospects of PCSK9-targeted therapies, and understand how these innovations are reshaping the landscape of cardiovascular disease treatment and prevention.
Overview
Syllabus
Pushing the Envelope with PCSK9-Twenty Years of Progress
Taught by
MonteHeart Lectures